Project Grant R43HL142319

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $323,230 to Sirona Medical Technologies, Inc. to develop a customizable, multi-channel, dual energy source generator for their cardiac ablation catheters. The goal is to create hardware that can interface Sirona's ablation catheters with radiofrequency (RF) and pulsed field (PF) energy sources, and establish safe and effective signal...

This $437,461 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), funded under the Cardiovascular Diseases Research program (CFDA 93.837), supports the development of a novel stabilization catheter device for His pacing lead implantation. The goal is to improve the accuracy and ease of His bundle pacing, an emerging alternative cardiac resynchronization therapy (CRT) for heart failure patients. The project aims to refine a deployable suction-tipped lead...

The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) awarded Sigt LLC a $293,880 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program. The purpose of this Phase 1 SBIR grant is to develop a novel "Intraoperative Cardiac Pulsed Field Ablation Lesion Assessment System" (PFA-LAS) that can monitor procedure parameters and confirm durable lesion formation during cardiac pulsed electric field ablation procedures for atrial...

This $866,240 National Institutes of Health National Heart, Lung and Blood Institute project grant funds the development of an innovative ablation system for inoperable hypertrophic cardiomyopathy patients at the University of Texas at Arlington from September 1, 2022 to August 31, 2025. The university researchers aim to design a controllable, localized ablation method to replace alcohol ablation and its risks. They will develop a collagenase-coated, doxorubicin-loaded degradable nanoparticle...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $413,595 to Unandup, LLC to develop a magnetic rotational atherectomy platform for treating coronary lesions in cardiovascular disease. The key products to be delivered include an over-the-wire atherectomy device controlled by magnetic fields, which aims to enable safer and more effective debulking of severely calcified lesions compared...

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Cooperative Agreement award of $1,000,000 to Theromics Inc., a minority-owned small disadvantaged business, aims to develop a novel protein-based gel to improve the effectiveness and safety of thermal tumor ablation procedures. The project will involve creating a computational model to predict the thermal behavior of the gel, conducting preclinical studies to quantify temperatures, ablation zone size,...

The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) federal grant program, awarded a $2,290,407 Project Grant to the University of Utah to advance the use of radiation as a non-invasive means of ablation for ventricular tachycardia (VT). The key goals of the 4-year project are to: 1) determine the dose response and structural/functional effects of radiation on cardiac tissue, 2) create radiation targeting strategies using personalized...

The National Science Foundation awarded a $255,731 Small Business Innovation Research Phase I Project Grant to Senoguard Inc. under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084). The grant funds the development and preclinical testing of a novel cryoablation probe system for post-lumpectomy margin ablation cancer treatment. Specifically, the company will design and optimize the probe for optimal contact and thermal transfer with tumor cells in fixed in vitro testing. The...

The National Science Foundation (NSF) awarded a $275,000 Small Business Innovation Research (SBIR) Phase I project grant to Agil Therapeutics Inc. under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084). This two-year project aims to develop a novel cryoablation system for minimally invasive treatment of type 2 diabetes. The system is designed to deliver a highly controlled and targeted cryogenic agent to the duodenum, with the goal of remodeling the duodenal tissue to...

Alsus Medical Inc. received a $255,564 Project Grant award from the National Science Foundation under the Small Business Innovation Research (SBIR) program (CFDA 47.084) to develop a minimally invasive transurethral cryotherapy catheter system for benign prostate hyperplasia. The SBIR program funds the critical early stages of research and development for technologies with strong potential to meet federal research and development needs and transition to commercial applications. Under this...